IPSC — Century Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$2.06
+$0.03 (+1.48%)
Century Therapeutics Inc (IPSC) is a biotechnology company listed on NASDAQ. It is led by Brent Pfeiffenberger M.B.A., Pharm.D., based in 25 North 38th Street, Philadelphia, PA, United States, 19104, with about 140 employees. Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Latest reported IPSC revenue for 2025-09-30 was $109.2M. Net income was $9.6M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. IPSC currently screens at market cap $47.8M.
Use this IPSC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IPSC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IPSC SEC filings page. Lician reads the product cache first so this HTML stays unique to Century Therapeutics Inc even when a live quote feed is slow.
About Century Therapeutics Inc
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC Key Statistics
Market Cap
$47.83M
Volume
542,770
Previous Close
$2.12
Day Range
$2.12 – $2.21
EPS
-$1.61
Revenue
$6.59M
Net Income
-$126.57M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+194.8%
Profit Margin
-1920.9%
Employees
140
IPSC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $6.59M | $2.23M | $5.20M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$126.57M | -$136.67M | -$130.93M | -$95.82M |
| EPS (Diluted) | -$1.61 | -$2.30 | -$2.96 | -$2.96 |
Total Assets
$353.22M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$58.44M
Operating Cash Flow
-$110.14M
Free Cash Flow
$0.00
Century Therapeutics Inc Company Information
- President, CEO & Director
- Brent Pfeiffenberger M.B.A., Pharm.D.
- Headquarters
- 25 North 38th Street, Philadelphia, PA, United States, 19104
- Website
- www.centurytx.com
- Phone
- 267 817 5790
- IPO / Founded
- 2021-06-18
- Sector
- Healthcare
- Industry
- Biotechnology